Investigational drug · Phase 3
EX-03
Also called: EscharEx, 5% EscharEx
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Venous Leg Ulcer (VLU), Venus Leg Ulcers.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
3
Any phase or sponsor naming "EX-03"
First trial start
2025
Jun 1, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "EX-03", any sponsor or status.
Conditions studied
As listed on its trial records.
- Venous Leg Ulcer (VLU)
- Venus Leg Ulcers
Largest trials
Live from ClinicalTrials.gov: studies naming "EX-03" as an intervention, largest first.
- A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)Pivotal-lookingRecruiting
MediWound LtdIndustry
NCT06568627 · 216 participants (planned) · Start Jun 1, 2025 · Primary completion Dec 2026
Drug: EscharEx (EX-03); Placebo (Gel vehicle) · For: Venous Leg Ulcer (VLU)
Sites: Phoenix, Arizona; Fresno, California; Los Angeles, California · 60 sites in all
MediWound LtdIndustry
NCT06690177 · 45 participants (planned) · Start Jan 10, 2027 · Primary completion Nov 4, 2028
Drug: EscharEx (EX-03); Placebo (Gel vehicle) · For: Venus Leg Ulcers
Sites: Maimi, Florida; Warsaw, Poland
MediWound LtdIndustry
NCT07692178 · 20 participants (planned) · Start Aug 2026 · Primary completion Aug 2028
Drug: EX-03 · For: Venous Leg Ulcer (VLU)
Newest research
PubMed records naming it or its code names, newest first.
- Once daily Bromelain-based enzymatic debridement of venous leg ulcers versus gel vehicle (placebo) and non-surgical standard of care: a three-arm multicenter, double blinded, randomized controlled study.
Shoham Y, Snyder RJ, Katz Levy Y, et al. · EClinicalMedicine 2024
- Bromelain-based enzymatic debridement of chronic wounds: Results of a multicentre randomized controlled trial.
Shoham Y, Shapira E, Haik J, et al. · Wound Repair Regen 2021
- Development of a porcine hard-to-heal wound model: evaluation of a bromelain-based enzymatic debriding agent.
Shoham Y, Sabbag I, Singer AJ · J Wound Care 2021
- Development of a contaminated ischemic porcine wound model and the evaluation of bromelain based enzymatic debridement.
Singer AJ, Toussaint J, Chung WT, et al. · Burns 2018
- Experience with a new hemodialyzer, the EX-03 Dialyzer Cartridge.
Reddy CR, Gara AH, Bergman LA, et al. · Chic Med Sch Q 1970
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.